Have a personal or library account? Click to login
Implementing an Antimicrobial Stewardship Program and Complete Screening in an Intensive Care Unit in Relation to the Overall Clinical Outcome of Patients Cover

Implementing an Antimicrobial Stewardship Program and Complete Screening in an Intensive Care Unit in Relation to the Overall Clinical Outcome of Patients

Open Access
|Dec 2024

References

  1. Le Saux N. Antimicrobial stewardship in daily practice: Managing an important resource. Paediatr Child Health. 2014;19(5):261-270. doi:10.1093/pch/19.5.261
  2. Ture Z, Güner R, Alp E. Antimicrobial steward-ship in the intensive care unit. J Intensive Med. 2022;3(3):244-253. Published 2022 Nov 15. doi:10.1016/j.jointm.2022.10.001
  3. Kyriazopoulou E, Giamarellos-Bourboulis EJ. Antimicrobial Stewardship Using Bio-markers: Accumulating Evidence for the Critically Ill. Antibiotics (Basel). 2022;11(3):367. Published 2022 Mar 9. doi:10.3390/antibiotics11030367
  4. Moniz P, Coelho L, Póvoa P. Antimicrobial Stewardship in the Intensive Care Unit: The Role of Biomarkers, Pharmacokinetics, and Pharmacodynamics. Adv Ther. 2021;38(1):164-179. doi:10.1007/s12325-020-01558-w
  5. Nora D, Salluh J, Martin-Loeches I, Póvoa P. Bio-marker-guided antibiotic therapy-strengths and limitations. Ann Transl Med. 2017;5(10):208. doi:10.21037/atm.2017.04.04
  6. Cortegiani A, Antonelli M, Falcone M, et al. Rationale and clinical application of antimicrobial stewardship principles in the intensive care unit: a multidisciplinary statement. J Anesth Analg Crit Care. 2023;3(1):11. Published 2023 May 1. doi:10.1186/s44158-023-00095-6
  7. Lawrence KL, Kollef MH. Antimicrobial stewardship in the intensive care unit: advances and obstacles. Am J Respir Crit Care Med. 2009;179(6):434-438. doi:10.1164/rccm.200809-1394CP
  8. Zilahi G, Artigas A, Martin-Loeches I. What's new in multidrug-resistant pathogens in the ICU?. Ann Intensive Care. 2016;6(1):96. doi:10.1186/s13613-016-0199-4
  9. Martín-Loeches I, Diaz E, Vallés J. Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care. 2014;20(5):516-524. doi:10.1097/MCC.0000000000000124
  10. Raut M, Schein J, Mody S, et al. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Curr Med Res Opin. 2009;25(9):2151-2157. doi:10.1185/03007990903102743
  11. Tanaka C, Tagami T, Kuno M, et al; DIANA Study Japanese Group. Evaluation of clinical response to empirical antimicrobial therapy on day 7 and mortality in the intensive care unit: sub-analysis of the DIANA study Japanese data. Acute Med Surg. 2023;10(1):e842. Published 2023 May 17. doi:10.1002/ams2.842
  12. Vlak I, Samardžić I, Marinović I, et al. Antimicrobial Stewardship and Dose Adjustment of Restricted Antimicrobial Drugs in Hospital Setting. Pharmacy (Basel). 2023;11(2):68. Published 2023 Apr 2. doi:10.3390/pharmacy11020068
  13. Hughes S, Heard KL, Mughal N, et al. Optimization of antimicrobial dosing in patients with acute kidney injury: a single-centre observational study. JAC Antimicrob Resist. 2022;4(4):dlac080. Published 2022 Jul 25. doi:10.1093/jacamr/dlac080
  14. Pulcini C, Binda F, Lamkang AS, et al. Developing core elements and checklist items for global hospital antimicrobial stewardship programmes: a consensus approach. Clin Micro-biol Infect. 2019;25(1):20-25. doi:10.1016/j. cmi.2018.03.033
  15. Kollef MH, Bassetti M, Francois B, et al. The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Med. 2017;43(9):1187-1197. doi:10.1007/s00134-017-4682-7
  16. De Waele JJ, Akova M, Antonelli M, et al. Antimicrobial resistance and antibiotic steward-ship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Med. 2018;44(2):189-196. doi:10.1007/ s00134-017-5036-1
  17. Bonten MJ, Weinstein RA. The role of colonization in the pathogenesis of nosocomial infections. Infect Control Hosp Epidemiol. 1996;17(3):193-200. doi:10.1086/647274
  18. Kurukulasooriya MRP, Tillekeratne LG, Wijayaratne WMDGB, et al. Methicillin-resistant Staphylococcus aureus: prevalence of and risk factors associated with colonization of patients on admission to the Teaching hospital, Karapitiya. J Univ Ruhuna 2018;6(2):70–75. doi: 10.4038/jur.v6i2.7878
  19. Reuken PA, Torres D, Baier M, et al. Correction: Risk Factors for Multi-Drug Resistant Pathogens and Failure of Empiric First-Line Therapy in Acute Cholangitis. PLoS One. 2017;12(2):e0172373. Published 2017 Feb 13. doi:10.1371/journal.pone.0172373
  20. Joung MK, Lee JA, Moon SY, et al. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care. 2011;15(2):R79. doi:10.1186/cc10072
  21. Morel J, Casoetto J, Jospé R, et al. De-escalation as part of a global strategy of empiric anti-biotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care. 2010;14(6):R225. doi:10.1186/cc9373
  22. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(5):913-920. doi:10.1093/jac/ dkm318
  23. Williams TA, Ho KM, Dobb GJ, et al. Effect of length of stay in intensive care unit on hospital and long-term mortality of critically ill adult patients. Br J Anaesth. 2010;104(4):459-464. doi:10.1093/bja/aeq025
DOI: https://doi.org/10.2478/prilozi-2024-0019 | Journal eISSN: 1857-8985 | Journal ISSN: 1857-9345
Language: English
Page range: 13 - 24
Published on: Dec 12, 2024
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2024 Jelena Micik, Aleksandar Dimovski, Zoran Sterjev, Ljubica Shuturkova, Aleksandra Grozdanova, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.